European journal of gastroenterology & hepatology · 2012
Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Liping, Chen Huan, Wen Quan, Zhang Yan
Аннотация
OBJECTIVE: The study is carried out to identify the expression pattern of indoleamine 2,3-dioxygenase (IDO) in human Crohn's disease and ulcerative colitis and to investigate the effect of different therapies (salicylates, steroids, and antitumor necrosis factor antibody) on the intestinal expression of IDO.
METHODS: Immunohistochemistry was used. A total of 10 high power fields were counted for each patient.
RESULTS: IDO was expressed in the both lamina propria and epithelium. IDO expression increased in the lesions from ulcerative colitis and Crohn's disease and was positively related to the severity of inflammation. IDO-positive mononuclear cells also expressed CD11c, CD68, and TLR4. IDO expression decreased significantly after treatment with steroids and salicylates, but remained unchanged after infliximab therapy.
CONCLUSION: IDO was over-expressed in human inflammatory bowel disease. It may be a bridge between innate immunity and adaptive immunity. Steroids and salicylates may act through the inhibition of IDO expression. IDO upregulation may be a promising therapy to achieve inflammatory bowel disease remission.
METHODS: Immunohistochemistry was used. A total of 10 high power fields were counted for each patient.
RESULTS: IDO was expressed in the both lamina propria and epithelium. IDO expression increased in the lesions from ulcerative colitis and Crohn's disease and was positively related to the severity of inflammation. IDO-positive mononuclear cells also expressed CD11c, CD68, and TLR4. IDO expression decreased significantly after treatment with steroids and salicylates, but remained unchanged after infliximab therapy.
CONCLUSION: IDO was over-expressed in human inflammatory bowel disease. It may be a bridge between innate immunity and adaptive immunity. Steroids and salicylates may act through the inhibition of IDO expression. IDO upregulation may be a promising therapy to achieve inflammatory bowel disease remission.
Предметные рубрики MeSH
AdultAnti-Inflammatory Agents, Non-SteroidalAntibodies, MonoclonalAntigens, CDAntigens, Differentiation, MyelomonocyticCD11c AntigenColitis, UlcerativeCrohn DiseaseEpithelial CellsFemaleGastrointestinal AgentsGlucocorticoidsHumansImmunoenzyme TechniquesIndoleamine-Pyrrole 2,3,-DioxygenaseInflammatory Bowel DiseasesInfliximabIntestinal MucosaMaleMiddle AgedSalicylatesToll-Like Receptor 4Tumor Necrosis Factor-alphaCD68 Molecule